Related Experiment Video
Updated: Jun 27, 2026

Rapid In Vivo Assessment of Adjuvant's Cytotoxic T Lymphocytes Generation Capabilities for Vaccine Development
Published on: June 19, 2018
Human vaccine research in the European Union
Ole F Olesen1, Anna Lonnroth, Bernard Mulligan
1Health Directorate, DG Research, European Commission, Rue de la Loi 200, B-1049 Brussels, Belgium. ole.olesen@ec.europa.eu
Abstract:
The use of vaccines is saving millions of lives every year across the globe, but a number of important diseases such as HIV/AIDS, malaria, TB and hepatitis C continue to frustrate attempts to produce effective vaccines against them. Confronting these challenges will require new approaches and increased research efforts by the scientific community. The Sixth Framework Programme (FP6; 2002-2006) of the European Commission (EC) has been an important catalyst in this direction by allocating a financial contribution of more than EUR 210 million to a wide variety of vaccine research activities, ranging from basic vaccinology, translational research to clinical application of vaccines. Taken together, around 581 research groups from 52 countries are participating in the vaccine activities of FP6. This impressive number signals a new spirit of collaborative research, which will facilitate the exploitation of the immense possibilities in modern vaccinology.
Related Concept Videos
Vaccine Production
Cross-reactivity
Vaccinations
Vaccines
Microorganisms in Medicine and Therapeutics
Humoral Immune Responses

